STRATEC SE

Earnings Release • Oct 23, 2008

News Details

Ad-hoc | 23 October 2008 12:04

STRATEC presents preliminary figures for the first nine months of 2008

STRATEC Biomedical Systems AG / Quarter Results/Preliminary Results

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

STRATEC presents preliminary figures for the first nine months of 2008

Birkenfeld, October 23, 2008

The Board of Management of STRATEC Biomedical Systems AG, which is listed
in the Prime Standard, hereby announces the preliminary unaudited
consolidated figures of the STRATEC Group for the first nine months of the
2008 financial year pursuant to IFRS (International Financial Reporting
Standards) and in accordance with Section 15 of the German Securities
Trading Act (WpHG).

Key Figures (EUR 000s) 01.01.- 09.30.2008 01.01.- 09.30.2007 Change
Sales 44,255 50,526 -12.4%
Gross performance 48,595 52,239 -7.0%
EBITDA 8,964 11,616 -22.8%
EBIT 7,240 9,970 -27.4%
EBT 7,530 10,058 -25.1%
Consolidated net income 5,702 7,011 -18.7%
Earnings per share (EUR) 0.50 0.62 -19.4%

Including temporary employees, the STRATEC Group had a total of 274
employees as of September 30, 2008 (previous year: 269).

The third quarter of the previous year benefited from a positive one-off
item in the form of a non-operating special payment contributing Euro 0.8
million to EBIT. Adjusted for this one-off item, consolidated net income
fell by 12.4%, and thus in line with the sales performance, in the first
nine months of 2008.

---

Information and Explaination of the Issuer to this News:

STRATEC’s business performance met expectations in the third quarter of
2008.

For the fourth quarter of 2008 our customers have already placed their
orders. The postponement of an order 2008 expected from one customer for
the fourth quarter was disclosed in the ad-hoc announcement published on
September 30, 2008. Apart from this, all other customers have confirmed,
and in some cases increased, their previously communicated purchase
forecasts. We therefore do not expect to see any further postponements or
cancellations in the collection of analyzer systems in the fourth quarter
of 2008.

The long-term growth in our company is based on a large number of
development and supply contracts already agreed. The development status of
existing cooperation projects, as well as new customer orders currently
being initiated, give grounds to expect an ongoing positive business
performance. In view of its positive cash flow and high volume of
liquidity, STRATEC is able to safeguard the planned growth of the company
on a long-term basis.

Current purchase forecasts of our customers, coupled with the pending
market launch of systems currently in the final stages of the development
pipeline, mean that there is substantial growth potential from 2009
onwards. STRATEC therefore expects to be able to achieve its previously
published average annual growth rates (CAGR 2009 - 2011) of more than 11%
for sales and more than 18% for earnings before taxes (EBT). In particular,
considerably stronger growth is now expected for 2009 given this reduction
in the estimates for 2008.

The extensive 'Interim report as of September 30, 2008' will be available
for downloading from our internet site from around 3 p.m. (CET) on November
18, 2008.

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated analyzer systems for its partners in the
fields of clinical diagnostics and biotechnology. These partners market
such systems, in general together with their own reagents, to laboratories,
blood banks and research institutes around the world. The company develops
its products on the basis of its own patented technologies. Shares in the
company (ISIN: DE0007289001) are traded in the Prime Standard segment of
the Frankfurt Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.

Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email: ir@stratec-biomedical.de
23.10.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---